Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Clinical trials are categorized as industry sponsored trials (ISTs) or investigator-initiated trials (IITs) based on the source of funding and sponsor of the trial. ISTs are usually run by pharmaceutical companies, and are primarily aimed at developing new drugs that ultimately gain regulatory approval. IITs are developed by academic investigators or cooperative groups, often sparked by a clinical need. Both are vital in advancing the field of oncology. To date, little has been published about current trends in ISTs or IITs in genitourinary (GU) oncology. The aim of this study was to assess growth trends of GU oncology ISTs and IITs in 4 countries with similar healthcare infrastructures.
Methods: We searched ClinicalTrials.gov for bladder, kidney, and prostate cancer trials conducted in the United States (US), Canada, France, and United Kingdom (UK) from January 2007 to December 2021. Trials were determined to be ISTs or IITs based on their funding source and sponsor. Trials were characterized based on type, purpose, phase, participants, masking, assignment, and allocation.
Results: Overall, 5,834 GU trials were identified, with a balanced distribution of ISTs (n = 3064, n = 52.5%) and IITs (n = 2770, 47.4%). By country, the US conducted the most GU trials (n = 3814) followed by Canada (n = 709), France (n = 677), and the UK (n = 634). Most ISTs were phase 3 trials with over 500 participants while most IITs were open-label phase 2 studies with only 20-49 participants. From 2017 onwards, there was a shift towards more ISTs, most noticeably in Canada and the UK. The COVID-19 pandemic did not have a major impact on the growth of ISTs and IITs.
Conclusion: The gap between ISTs and IITs continues to widen, likely driven by resource and funding challenges faced by investigators. Barriers to completing IITs need to be better understood to promote IIT development and maintain their academically driven intentions.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.clgc.2024.102210 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Investigator-initiated versus industry-sponsored trials - visibility and relevance of randomized controlled trials in clinical practice guidelines (IMPACT).
BMC Med Res Methodol
March 2025
Freiburg Center for Data Analysis, Modeling and AI, University of Freiburg, Ernst-Zermelo-Str. 1, 79104, Freiburg, Germany.
Background: The goal of evidence-based medicine is to make clinical decisions based on the best available, relevant evidence. For this to be possible, studies such as randomized controlled trials (RCTs), which are widely considered to provide the best evidence of all forms of primary research, must be visible and have an impact on clinical practice guidelines. We further investigated the impact of publicly and commercially sponsored RCTs on clinical practice guidelines by measuring direct and indirect impactful citations and the time to guideline impact.
View Article and Find Full Text PDFMapping the cell therapy landscape: insights into clinical trials and regulatory advances in China.
J Hematol Oncol
October 2024
Vanke School of Public Health, Tsinghua University, Beijing, China.
Article Synopsis
- * China's dual-track regulatory framework has led to it becoming the second largest nation for cell therapy clinical trials, with a significant focus on hematologic malignancies despite a high demand for treatments for solid tumors.
- * The study reveals that over 90% of cell therapy trials in China are investigator-initiated, highlighting the need for stricter regulations and guidelines to minimize redundant research and promote value-driven product development.
Comparison of Industry-Sponsored Trials (IST) and Investigator-Initiated Trials (IIT) in Advanced Genitourinary Cancers in the United States, Canada, United Kingdom and France.
Clin Genitourin Cancer
December 2024
Princess Margaret Cancer Center, Toronto, Ontario, Canada.
Article Synopsis
- Clinical trials in genitourinary oncology are primarily classified as industry-sponsored trials (ISTs) led by pharmaceutical companies, or investigator-initiated trials (IITs) spearheaded by academic researchers, with both playing critical roles in advancing cancer treatment.
- A study analyzing data from the US, Canada, France, and the UK found a total of 5,834 GU trials from 2007 to 2021, with a near-equal distribution of ISTs and IITs, though post-2017 saw a notable increase in ISTs, particularly in Canada and the UK.
- The widening gap between ISTs and IITs is likely due to funding and resource constraints for researchers
Development of clinical trials for non-small cell lung cancer drugs in China from 2005 to 2023.
Front Med (Lausanne)
November 2023
Clinical Science of Stomatology, Chi Feng Municipal Hospital, Chifeng, China.
Objective: Over the past few decades, the development of anti-cancer drugs in China has made outstanding achievements based on the support of national policies. To assess the progress of non-small cell lung cancer (NSCLC) drugs, we conducted a statistical analysis of clinical trials of drugs targeting NSCLC in China from 2005 to 2023.
Methods: We downloaded, screened and analysed the data from three official websites, the Centre for Drug Evaluation of China National Medical Products Administration website (NMPA), ClinicalTrials.
Evolution of ischemic stroke drug clinical trials in mainland China from 2005 to 2021.
CNS Neurosci Ther
August 2022
Department of Neurology, Department of General Surgery, China National Clinical Research Center for Geriatric Diseases, XuanWu Hospital, Capital Medical University, Beijing, China.
Background: To assess the temporal changes in the characteristics of ischemic stroke drug clinical trials conducted in mainland China in 2005-2021.
Methods: A statistical analysis of registered clinical trials on ischemic stroke was performed using the platform of the Center for Drug Evaluation of China National Medical Products Administration, the Chinese Clinical Trial Registry, and ClinicalTrials.gov websites.